Denali TherapeuticsDNLI
DNLI
About: Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.
Employees: 390
0
Funds holding %
of 7,139 funds
0
Analysts bullish %
of 6 analysts
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
100% more funds holding in top 10
Funds holding in top 10: 1 [Q3] → 2 (+1) [Q4]
80% more call options, than puts
Call options by funds: $1.35M | Put options by funds: $750K
34% more repeat investments, than reductions
Existing positions increased: 82 | Existing positions reduced: 61
32% more first-time investments, than exits
New positions opened: 41 | Existing positions closed: 31
2% more funds holding
Funds holding: 216 [Q3] → 221 (+5) [Q4]
0.45% more ownership
Funds ownership: 88.43% [Q3] → 88.88% (+0.45%) [Q4]
29% less capital invested
Capital invested by funds: $3.69B [Q3] → $2.61B (-$1.08B) [Q4]
Research analyst outlook
6 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$24
16%
upside
Avg. target
$42
101%
upside
High target
$87
320%
upside
6 analyst ratings
6 positive
100%
0 neutral
0%
0 negative
0%
Deutsche Bank David Hoang 38% 1-year accuracy 8 / 21 met price target | 50%upside $31 | Buy Initiated | 11 Feb 2025 |
Goldman Sachs Salveen Richter 27% 1-year accuracy 4 / 15 met price target | 93%upside $40 | Buy Maintained | 28 Jan 2025 |
JP Morgan Jessica Fye 69% 1-year accuracy 27 / 39 met price target | 16%upside $24 | Overweight Maintained | 7 Jan 2025 |
HC Wainwright & Co. Andrew Fein 36% 1-year accuracy 125 / 348 met price target | 320%upside $87 | Buy Maintained | 7 Jan 2025 |
Baird Joel Beatty 53% 1-year accuracy 21 / 40 met price target | 50%upside $31 | Outperform Initiated | 7 Jan 2025 |
Financial journalist opinion
Positive
Zacks Investment Research
2 weeks ago
DNLI Reports Upbeat Longer-Term Data From Hunter Syndrome Study
Denali announces encouraging additional longer-term data from the phase I/II Hunter Syndrome study of its investigational therapy, tividenofusp alfa.
Neutral
GlobeNewsWire
2 weeks ago
Denali Therapeutics Announces Primary Analysis and Long-Term Follow-Up of Phase 1/2 Study in Hunter Syndrome (MPS II) with Tividenofusp Alfa
SOUTH SAN FRANCISCO, Calif., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), today announced the primary analysis of the Phase 1/2 study in 47 participants with Hunter syndrome (MPS II) in the 24-week treatment period and additional long-term follow-up of its investigational therapeutic tividenofusp alfa (DNL310). These data, along with recent Breakthrough Therapy designation, further support the company's plan to submit a biologics license application (BLA) in early 2025 for accelerated approval and deliver this potential treatment to the Hunter syndrome community in late 2025 or early 2026. The Phase 1/2 results are being presented this week at the 21st Annual WORLDSymposium™ conference in San Diego, California.
Positive
Zacks Investment Research
1 month ago
Denali Gains 26.6% in a Year: How Should You Play the Stock?
DNLI has had a good run in the past year on positive pipeline updates. A potential approval of its Hunter Syndrome drug should be a boost.
Neutral
Benzinga
1 month ago
Why Is Denali Therapeutics Stock Trading Higher On Wednesday?
Denali Therapeutics Inc DNLI CEO Ryan Watts presented at the J.P. Morgan Healthcare Conference.
Negative
Seeking Alpha
1 month ago
Denali: Despite ALS Primary Endpoint Failure, Possible Path Forward Remains
Denali Therapeutics Inc.'s DNL343 failed to meet the primary endpoint in the phase 2/3 HEALY ALS trial, but potential biomarker analyses in 2025 may offer a path forward. Despite the trial setback in ALS, Denali's stock remains stable due to continued pre-specified analyses expected in late 2025. BLA filing of tividenofusp alfa for the treatment of patients with MPS II remains on track under the Accelerated Approval Pathway Program in early 2025.
Positive
Zacks Investment Research
1 month ago
DNLI's Hunter Syndrome Drug Gets Breakthrough Therapy Designation
Denali obtains Breakthrough Therapy Designation for its experimental candidate, tividenofusp alfa (DNL310), for the treatment of pateints with Hunter syndrome.
Negative
Zacks Investment Research
1 month ago
Denali's ALS Study Fails to Meet Primary and Secondary Endpoints
DNLI's DNL343 fails to achieve the primary and secondary endpoints, as observed from an analysis of Regimen G of the phase II/III HEALEY ALS platform trial.
Positive
Investors Business Daily
1 month ago
Denali Reverses Its Fortunes With 'Too Early' Miss In ALS Treatment
Denali Therapeutics shares reversed higher on Tuesday after the drugmaker's ALS treatment failed in a six-month study. The post Denali Reverses Its Fortunes With 'Too Early' Miss In ALS Treatment appeared first on Investor's Business Daily.
Negative
Reuters
1 month ago
Denali Therapeutics ALS drug fails in mid-stage trial
Denali Therapeutics said on Monday its experimental drug failed to meet the main goal of a mid-to-late stage trial in patients with amyotrophic lateral sclerosis (ALS), a fatal neurodegenerative disease.
Neutral
GlobeNewsWire
1 month ago
Denali Therapeutics Announces Topline Results for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial
SOUTH SAN FRANCISCO, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI) today announced topline results from an analysis of Regimen G of the Phase 2/3 HEALEY ALS Platform Trial evaluating eIF2B agonist DNL343 in the treatment of amyotrophic lateral sclerosis (ALS).
Charts implemented using Lightweight Charts™